Despite near ubiquity, information regarding fluids consumption at a health care systems level, and patient exposure at an individual level, is surprisingly limited in the medical literature. The epidemiology of the foundational medical intervention of intravenous fluid administration is incredibly complex, with millions of patients being exposed internationally every year. Fluid is being given for different reasons, to different targets, following different triggers, by different specialties in different countries, and any observations that can be made are thought to have limited external validity to other jurisdictions and patient groups. The independent effects of fluid administration and fluid accumulation are very hard to separate from other markers of illness severity and aspects of the process of care. Fluid accumulation can result in organ injury, even when the fluid is being given to purportedly ameliorate or prevent such injury, and if it were independently associated with mortality then would be an easily accessible and modifiable risk factor for subsequent morbidity or death. Despite their ubiquity, it is clear that we have limited understanding of the effects of the intravenous fluids we use daily in the most vulnerable of patient groups. The research agenda in this field is large and urgent. [ 10, 11] cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
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Original Articles
Implementing a Sepsis Resuscitation Bundle Improved Clinical Outcome: A Before-and-After Study The only published data on crystalloid solutions that we could identify reported that 10 million litres of 0.9% saline were sold in the UK in 1999, though the source of this data is uncertain. [12] Given that 8.7 million litres of saline were sold to the public health system over the 2013-14 financial year in Australia and New Zealand, [13] a region with approximately 1/3 of the population of the UK, this figure is likely to be a substantial underestimate.
The same source suggested more than 200 million litres of saline are purchased annually in the USA, [12] but a 2013 New York Times article places recent consumption at up to 1 billion units each year. [14] Recent media reports suggested that China may use up to 10 billion units of intravenous fluid, though subsequent government reports stated this figure represents the national production, not consumption, of intravenous fluids. [15] In addition, complex cultural factors suggest significant over-prescription and over-use of parenteral therapies in China. [16] No such information is available for other countries, including South Korea.
Regarding colloid solutions, in a personal communication from an employee of Fresenius Kabi, the world market for colloid consumption in 1994 was estimated at almost 500 million units. [17] In an analysis of reported adverse event using data supplied to the Plasma Protein Therapeutics Association by its constituent member companies, approximately 16 million litre-equivalents of 4% albumin solution were supplied between 1998 and 2000 internationally. [18] A subsequent investigation examining colloid use in 16 industrialised countries found acquiring data to be very difficult. Only limited data on albumin could be acquired from 15 of the 16 countries, and data regarding synthetic colloid use was only obtainable from 3. In 2004 more than 230,000 litres of synthetic colloids were used in Canada. In Denmark, in 2005, more than 100,000 litres were used and in Sweden more than 170,000 litres were used over the same time period. [19] Over a five-year period the National Health Service in the UK spent approximately £156 million per annum on intravenous fluids, which could allow for an estimation of volume. [2] Unfortunately, the British National Formulary does not contain information on the cost of 500 mL and 1,000 mL bags of different crystalloid solutions, nor does this information appear to be available from other sources. In our institution, a 1,000 mL bag of 0.9% saline costs $AUD 1.10 and sales of intravenous and dialysis fluids in the state of Victoria are estimated to be worth $15 million. [20] However, we were unable to find any centralised estimates of healthcare expenditure for intravenous fluids in the USA or Australia, and extrapolating use from these figures would be complex, both because of regional and sectorial variation in healthcare purchasing and procurement strategies, and the pricing of such therapies. [14, 20] Surrogates of fluid exposure
In the absence of significant peer-reviewed literature, one method of estimating intravenous global fluid exposure may be by quantifying intravenous cannula use.
Five million intravenous cannula devices were used in Australian hospitals in 1994. [21] Assuming a conservative average increase in hospital admission rates of 3% per annum, [22] it is likely that there are now more than 9 million cannulations, and hence at least this many probable exposures to intravenous fluids, per year in
Australia. An apparent 150 to 200 million intravascular devices are purchased each year in the USA and used in approximately 30 million people. [23, 24] However, these numbers appear to be projections based on unpublished data [25] and observations more than 35 years old, [26] and so the true current rate of intravenous cannulation in the USA is uncertain. We were unable to identify similar information for UK cannulation rates, and it would seem that extrapolating fluid exposure from cannulation data would be unreliable for many reasons. We could not identify such information for South Korea. It is accepted by the UK National Health Service that there is no extant information on the proportion of patients receiving intravenous fluid therapy, but there are more than 5 million acute hospital admissions per year, and it is likely that the majority are exposed to intravenous fluid therapy. [28] In Australia in 2013-14 there were 9.7 million hospital admissions; 25% were emergency admissions and 20% admissions for surgical intervention.
Given that a further 1.3 million people were admitted for dialysis that financial year, it is likely that more than 5 million Australians are exposed to intravenous fluids on an annual basis. [22] In 2010, 136.3 million patients attended the emergency department in the USA, with 16.2 million being subsequently admitted and 2.1 million of those being admitted to ICU; [29] there were more than 35 million acute hospital admissions over this time period. [30] From these figures it is likely that between 15 and 30 million exposures to intravenous fluids occur annually in the US, though this is, at best, a rough estimate.
This is likely to translate into somewhere between 1 and 3 million patients being exposed to IV fluids in South Korea.
Proprietary information on fluid sales and similar in-
terventions is available, and may be more reliable than these other attempts at quantification. [31] Reports are available at a cost of thousands of dollars to guide companies seeking to invest or venture into the international intravenous fluid market, a market estimated to be worth an "outside context problem," in that it exists, and may be in some way injurious, though this was not anticipated before widespread use. [33] As a result, we have no way to quantify the harm that may ensure, but continue to use intravenous fluids with the ill-defined risks that they may pose, with the assumption that they are safe, because we all use them.
The complexities of early fluid resuscitation in sepsis
Exploration of the global population risks of intra- 
A bundle of disparate interventions
Emerging evidence over the last decade has suggested that several key aspects of the EGDT bundle are unlikely to be associated with benefit. For example, the Transfusion Requirements in Septic Shock (TRISS) trial, a multi-centre randomised controlled trial from more than 30 centres across Scandinavia, demonstrated no mortality benefit or differences in organ support or ischaemic events from transfusing red cells at a haemoglobin trigger of 9 g/dL compared to 7 g/dL in patients with septic shock, with a significant reduction in product usage. [47] The relatively liberal or non-specific transfusion thresholds of EGDT protocols are likely to lead to increased blood exposure for apparent minimal benefit in septic patients. 
Harmonising early resuscitative practice
Given these concerns, the publication of the Aus- Children without severe hypotension were randomised to receive 20 mL/kg 5% albumin, or 0.9% saline FBT or no FBT at all.
None of the resources of modern developed critical care practice were available, and no between AF and ICU mortality following adjustment for age, gender, body mass index, comorbidities, illness severity and sepsis severity at admission. AF both decreased the daily probability of ICU discharge, and increased the daily probability of death. [62] Unfortunately the relationship between AF and fluid balance remains unexplored in patients with sepsis, and in the larger critically ill population, but, given these findings may be an important consideration moving forward with studies with such definitions of septic shock.
The groups were unbalanced, with a suggestion that weight, source of sepsis, incidence of AKI and the vol- 
Adding insult to injury
Concern regarding tissue oedema and fluid overload has existed since the earliest days of fluid therapy, when it was still being delivered by "proctoclysis" (colonic administration). [63] Though not inevitable, the volume of fluid administered to critically ill patients as part of resuscitation, as a vehicle for drug administration, or in an attempt to optimised haemodynamics often leads to fluid accumulation, and the genesis of a positive fluid balance.
[64] This is exacerbated by the presence of comorbidities, such as chronic cardiac, liver, or kidney disease, acute interventions or pathological processes leading to admission, or the development of sequelae of those processes, such as acute kidney injury or multiple organ failure, which prevent elimination ( (Fig. 2) . [68] Restoration or protection of the glycocalyx may therefore provide a novel therapeutic target, [68] with syndecan-1 and hyaluronic acid offering promise as potential biomarkers of glycocalyceal disruption. [65, 66] Clearance of tissue and organ oedema relies on fluid shifting back into the intravascular space via the lymphatic system, the integrity and function of which remains poorly described during critical illness ( Fig.   1 ). [68, 69] The association between elevations in CVP and renal outcome discussed above are probably the most easily observable consequence of tissue oedema. As an encap- To describe the epidemiology of FO after cardiac surgery and if it is associated with worse clinical and respiratory outcomes in this population. Median of 30% of all IVF administered as FBT over ICU D1-2, 50% BP.
Peak cumulative FO% 7.4 ± 11.2% on ICU D2, independently associated with early IVF administration, cyanotic heart disease and first operation. D2 FO% was independently associated with greater PICU length of stay and duration of MV, adjusting for multiple clinical variables.
Paediatric critical care Ketheranathan, et al. [92] 2014
Retrospective singlecentre observational study in a South African academic paediatric ICU. 100 paediatric patients, median age 9 (2-39) months, 60% male, with PIM II score of 7 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) and 10% hospital mortality.
To assess the prevalence of FO and mortality, and the relationship between FO and patient centred outcomes and ventilatory parameters in this population. Greater volumes of PICU FBT and IVF given to non-survivors (12.5 Retrospective singlecentre observational study in a US academic paediatric ICU. 114 paediatric patients staying in the PICU for ≥ 48 h, median age 1.1 (0-17.4) years, 67% male, with PIM II score of 5.1 (0.2-99.3) and 13% hospital mortality. Excluded premature neonates or children admitted following surgery for congenital heart disease.
To explore the association of FB and mortality in children with sepsis and shock.
Small, heterogeneous sample. On Cox regression, independent association between mortality and FO > 10% on D3 ICU (HR 7.27), when adjusted for illness severity, infection or malignancy. On logistic multivariable regression independent association between peak cumulative FB on D3 and D7 with mortality when adjusted for illness severity, presence of infection, VA use or time to ICU admission. To explore the association of +FB and clinical outcomes in critically ill children with ALI. Possibly U-shaped relationship between +FB and mortality over the first 72 h when considered in 10 mL/kg/day increments. Increasing FB independently associated with duration of MV, and independently associated with mortality, when adjusted for organ system failures. sulated organ, increases in the renal volume will lead to rapid increases in intrarenal pressure and this, in turn, may reduce the trans-organ perfusion pressure gradient and hence organ blood flow. [48] [49] [50] [51] The overall effect of these processes may contribute to an increased vulnerability of the organ to subsequent insults, and concomitant organ failure (Fig. 2) . It is unclear if this relationship is unidirectional, but backpressure from the renal circulation may then contribute centrally to elevated right heart pressure through myocardial oedema, diastolic dysfunction and right heart dysfunction. operatively, [73] [74] [75] [76] in general critical illness, [77, 78] with sepsis/septic shock, [49, [79] [80] [81] with acute lung injury, [82] with malignancy, [83] and with AKI, [84] [85] [86] [87] [88] [89] [90] and in children post-cardiac surgery, [91] with general critical illness, [92, 93] with sepsis/septic shock, [94] [95] [96] and with acute lung injury. [97] [98] [99] [100] Table 2 presents select studies, published since 2010 and where n > 100, demonstrating persistent and pervasive associations between fluid balance, overload or accumulation and mortality in these patient groups, across a variety of circumstances, approaches and regions (Table 2) .
Evidence from Korea
Observational work offers some insights into local practice. [101] The association between changes in body weight and clinical outcomes were explored in a prospective observational study of 140 adult patients, 77% male, with a mean age of 66 years and a mean Acute Physiology and Chronic Health Evaluation Score (APACHE) II score of 20.6, admitted to the ICU of a Ko- Though admirable in its scope, the meta-analytic techniques utilised in this review are methodologically questionable given the mixing of randomised, observational and case-series data. Of particular interest is the authors attempt to begin to ontologically refine the language of fluid balance, administration and accumulation research.
[110] However, such definitions should come as the result of robust observational and pilot randomised data.
Moving forward
While observational data exploring fluid balance and outcomes are plentiful, and include relevant regional may be a safe mechanism to limit fluid administration.
[113] An alternative approach would be early vasoactive use after restricted initial resuscitation. While one study suggests early initiation of vasopressors may be harmful in the primary resuscitation phase, the data was collected over an 18-year period, [114] and an analysis of a larger data set by the same group suggests that marked delays of > 14 h are associated with increased mortality in patients with septic shock, not early initiation. 
